BILL ANALYSIS
HR1799
BULLISHFinancial Reporting Threshold Modernization Act
HR1799 (Financial Reporting Threshold Modernization Act) has been assessed with a bullish outlook for investors. This legislation directly affects Bank of America ($BAC), JPMorgan Chase ($JPM) and Wells Fargo ($WFC). The primary sectors impacted are Finance. View the full bill text on Congress.gov.
bullish
Market Sentiment
3
Affected Stocks
1
Sectors Impacted
Key Takeaways for Investors
HR1799 raises CTR threshold from $10,000 to $30,000 — first meaningful update since the original Bank Secrecy Act thresholds were set.
No federal funding authorized — impact is purely regulatory cost reduction for financial institutions.
Bill is active (Union Calendar) but has not passed the House; Senate companion bill has not been introduced.
Largest beneficiaries: large retail banks with high cash transaction volumes (JPM, BAC, WFC).
How HR1799 Affects the Market
This is a modest, incremental regulatory relief bill. It does not create new revenue streams or change interest margins. The market impact is neutral to slightly positive for bank stocks in the sector, but the effect is small relative to other drivers (net interest margin, credit cycles, regulation from the CFPB, Basel III endgame rules). Expect no material stock price reactions upon passage. The structural benefit is real — compliance cost savings compound annually — but the magnitude is unlikely to move earnings per share by more than low single digits for any covered bank.
Bill Details
| Metric | Value |
|---|---|
| Bill Number | HR1799 |
| Market Sentiment | bullish |
| Event Date | |
| Affected Sectors | Finance |
| Affected Stocks | Bank of America ($BAC), JPMorgan Chase ($JPM), Wells Fargo ($WFC) |
| Source | View on Congress.gov → |
Summary
HR1799, the Financial Reporting Threshold Modernization Act, raises CTR and SAR filing thresholds for the first time in decades, reducing compliance costs for banks. The bill is on the House Union Calendar after committee approval. No market-moving effect is expected — this is incremental regulatory relief, not a revenue-driven catalyst.